Evgen Pharma PLC Services Agreement with APTrans
13 February 2017 - 6:00PM
RNS Non-Regulatory
TIDMEVG
Evgen Pharma PLC
13 February 2017
13 February 2017
RNS REACH
Evgen Pharma plc
("Evgen Pharma" or the "Company")
Services Agreement with Drug Development Consortium
Evgen Pharma, a clinical stage drug development company focused
on cancer and neurological conditions, is pleased to announce the
signing of a services agreement with APTrans to support the ongoing
development of lead product, SFX-01. APTrans is a consortium of
drug development companies based in the Biohub at Alderley Park,
Cheshire.
APTrans works with clients to help them transform promising
molecules into valued medicines and was founded on the
complementary vision, values and expertise of three founding
companies:
-- Aptus Clinical, a specialist provider of Contract Clinical
Research Services focusing on innovative study design, high quality
conduct and exemplary delivery of early phase oncology studies
-- Apconix, a toxicology company at the forefront of innovative
thinking in nonclinical toxicology and safety science
-- Seda Pharmaceutical Development Services, an integrated
pharmaceutical development and clinical pharmacology service that
maximises value build
Dr Stephen Franklin, Founder and CEO of Evgen Pharma, said: "We
are delighted to have found a flexible way to access specialist
technical expertise and operational support to complement our
existing internal capabilities to support the ongoing development
of our lead product, SFX-01. We selected this excellent group of
providers as our partners as they have a proven track record of
working well together and they are all co-located at the Biohub
where we too have a presence."
Ned Wakeman, Director, Biohub at Alderley Park, commented: "The
APTrans initiative is a tangible example of how the environment
here can accelerate business value. The companies within APTrans
all spun out from AstraZeneca, participated in business
acceleration programmes, and are thriving in their own right. We
are passionate about nurturing an open and collaborative
environment where like-minded companies can work, socialise and
support each other, and are proud to share in the combined
successes of these great companies."
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466 5000
Dr Stephen Franklin, CEO
www.evgen.com
Buchanan
Mark Court, Sophie Cowles, Stephanie
Watson +44 (0) 20 7466 5000
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. It is also carrying out preclinical work in
multiple sclerosis and has a clinical interest in prostate cancer.
The Company's core technology is Sulforadex(R), a method for
synthesising and stabilising the naturally occurring compound
sulforaphane and novel proprietary analogues based on sulforaphane.
The lead product, SFX-01, is a patented composition of synthetic
sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its
registered office at the Liverpool Science Park and is a virtual
tenant at the Biohub at Alderley Park, Cheshire, UK. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG. For further information please visit
www.evgen.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADMGMZMZNGNZZ
(END) Dow Jones Newswires
February 13, 2017 02:00 ET (07:00 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024